Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer.
Zhao J, Wang L, Zhou A, Wen S, Fang W, Zhang L, Duan J, Bai H, Zhong J, Wan R, Sun B, Zhuang W, Lin Y, He D, Cui L, Wang Z, Wang J.
Zhao J, et al. Among authors: wen s.
Med. 2024 May 14:S2666-6340(24)00204-6. doi: 10.1016/j.medj.2024.04.011. Online ahead of print.
Med. 2024.
PMID: 38781965